Validating the European randomised study for screening of prostate cancer (ERSPC) risk calculator in a contemporary South African cohort

Abstract

Introduction

Numerous prostate cancer predictive tools have been developed to help with decision-making in men needing prostate biopsy. However, they have been modelled and validated almost exclusively in Caucasian cohorts, hence limiting their use in other population groups. The aim of this study was to assess the validity of the ERSPC risk calculator in a South African cohort.

Methods

Patients who have had a transrectal ultrasound (TRUS)-guided prostate biopsy at Groote Schuur Hospital from January 2008 to August 2017 were reviewed. Predictor variables were entered into the ERSPC risk calculator and results were compared with prostate biopsy pathology results. Predictive accuracy of the ERSPC risk calculator for these patients was derived using receiver operator characteristics (ROC) Area under the curve and is expressed as a percentage.

Results

516 prostate biopsy sessions in 475 different men were analysed. The predictive accuracy of the ERSPC risk calculator was better than a PSA/DRE strategy for the presence of cancer—0.738 (95% CI 0.695–0.781) vs 0.686 (95% CI 0.639–0.732), and for significant PCa—0.833 (95% CI 0.789–0.876) vs 0.793 (95% CI 0.741–0.846). This translated into 50 less biopsies when compared to a PSA > 4/abnormal DRE strategy. Use of the ERSPC RC would have missed eight non-significant cancers [Significant cancer being defined as having a tumour stage T2b (> 1/2 lobe involved with prostate cancer) and/or a Gleason Score equal to or greater than 7].

Conclusion

Our results confirm the validity of the ERSPC RC in a South African cohort. Application of this calculator to the wider South African population would allow better selection of patients for prostate biopsy and spare a significant number its adverse consequences.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. 1.

    Schroder FH, Hugosson J, Roobol MJ et al (2014) Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet (London, England). 384(9959):2027–2035

    Article  Google Scholar 

  2. 2.

    Loeb S, Bjurlin M, Nicholson J et al (2014) Overdiagnosis and overtreatment of prostate cancer. Eur Urol 65(6):1046–1055

    Article  Google Scholar 

  3. 3.

    Babb de Villiers C, Urban M, Kielkowski D et al (2014) Prostate cancer in South Africa: pathology based National Cancer Registry Data (1986–2006) and mortality rates (1997–2009). Prostate Cancer 2014

  4. 4.

    Schroder FH, Hugosson J, Carlsson S et al (2012) Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol 62(5):745–752

    Article  Google Scholar 

  5. 5.

    Gambert SR (2001) Screening for prostate cancer. Int J Nephrol Urol 33(2):249–257. https://doi.org/10.1023/A:1015290429403

    CAS  Article  Google Scholar 

  6. 6.

    Hugosson J, Carlsson S, Aus G et al (2010) Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11(8):725–732

    Article  Google Scholar 

  7. 7.

    van Vugt HA, Roobol MJ, Kranse R et al (2011) Prediction of prostate cancer in unscreened men: external validation of a risk calculator. Eur J Cancer 47(6):903–909

    Article  Google Scholar 

  8. 8.

    Cavadas V, Osorio L, Sabell F et al (2010) Prostate cancer prevention trial and European randomized study of screening for prostate cancer risk calculators: a performance comparison in a contemporary screened cohort. Eur Urol 58(4):551–558

    Article  Google Scholar 

  9. 9.

    Yoon DK, Park JY, Yoon S et al (2012) Can the prostate risk calculator based on western population be applied to asian population? Prostate 72(7):721–729

    Article  Google Scholar 

  10. 10.

    Trottier G, Roobol MJ, Lawrentschuk N et al (2011) Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort. BJU Int 108(8b):E237–E244

    Article  Google Scholar 

  11. 11.

    Rebbeck TR, Devesa SS, Chang BL et al (2013) Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of African descent. Prostate Cancer 2013:12 (Article ID 560857)

    Article  Google Scholar 

  12. 12.

    Foley RW, Maweni RM, Gorman L et al (2016) European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study. BJU Int 118(5):706–713

    Article  Google Scholar 

  13. 13.

    Poyet C, Nieboer D, Bhindi B et al (2016) Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (ERSPC) and Prostate Cancer Prevention Trial (PCPT) risk calculators: independent validation and comparison in a contemporary European cohort. BJU Int 117(3):401–408

    Article  Google Scholar 

  14. 14.

    Chang B-L, Spangler E, Gallagher S et al (2011) Validation of genome-wide prostate cancer associations in men of African descent. Cancer Epidemiol Biomark Prev 20(1):23–32

    CAS  Article  Google Scholar 

  15. 15.

    Ankerst DP, Boeck A, Freedland SJ et al (2012) Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol 30(2):181–187. https://doi.org/10.1007/s00345-011-0818-5

    Article  PubMed  Google Scholar 

  16. 16.

    Roobol MJ, van Vugt HA, Loeb S et al (2012) Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur Urol 61(3):577–583

    Article  Google Scholar 

  17. 17.

    van den Bergh RCN, Roobol MJ, Wolters T et al (2008) The Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: a comparison. BJU Int 102(9):1068–1073

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Contributions

BK protocol/project development, data collection or management, data analysis, manuscript writing/editing. MP data collection or management. BP data collection or management. MH data analysis. JL manuscript writing/editing.

Corresponding author

Correspondence to John Lazarus.

Ethics declarations

Conflict of interest

The authors declare no potential conflicts of interest.

Ethical approval

The research involved Human Participants. The study was approved by the Human Research Ethics Committee of the University of Cape Town. Reference Number: 324/2018.

Informed consent

No specific informed consent was obtained from the patients.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kowlessur, B., Phull, M., Patel, B. et al. Validating the European randomised study for screening of prostate cancer (ERSPC) risk calculator in a contemporary South African cohort. World J Urol 38, 1711–1718 (2020). https://doi.org/10.1007/s00345-019-02947-9

Download citation

Keywords

  • Prostate cancer
  • Risk calculator
  • Prognosis